Huntingdon Life Sciences and Harlan Laboratories to Become Envigo
News Jun 26, 2015
Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the combined companies will be called Envigo (pronounced En-vee-go.)
When the new name and brand is launched later this year it will be a significant milestone for the combined organization, marking great progress in integrating the companies and building on a heritage of more than 80 years.
The name Envigo is made from a combination of words that reflect the identity of the new company. The letters “E and N” come from “enhance, enrich and enable,” … the company helps make the world a better place through advancing the research and product development of its customers. “VIGO” originates in “vigorous and invigorate”, and the Latin word “vita” meaning “life”… so being dynamic and strong, imparting vitality, energy and life.
Brian Cass, CEO, commented: “This is a hugely exciting time for our company. We at Envigo will be united with our customers in the knowledge that the research they conduct, and the products we help them develop, have the potential to enhance life. Our new name and brand will reflect our integrated management structure and the broader product and service offerings of our combined organization.”
Adrian Hardy, COO, added: “Our customers are looking for partners who understand their goals, take ownership of projects, and deliver high quality products and science. Our goal is to establish Envigo as the number one partner for both customer service and scientific expertise.”
The combined organization has 3,800 people and sales approaching $500 million. As a result of the integration, the company is the largest provider of research services to the crop protection and chemical industries, the second largest supplier of research models and services, and the third largest in the preclinical pharmaceutical development arena.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE